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Abstract
Purpose: To determine if implementation of revised pain medication administration guidelines
in PACU led to improved patient satisfaction scores, lower pain scores at discharge from PACU,
lower pain medication and antiemetic medication costs in PACU, and shorter average PACU
length-of-stay (LOS) at the clinical site.
Background and Significance: Negative consequences of poorly managed acute postoperative
pain include diminished function and quality of life, compromised surgical recovery, extended
use of opioids, development of chronic postoperative pain, and increased morbidity and medical
costs (Gan, 2017). There is an impetus to minimize narcotic medications administered after
surgery, while still providing adequate pain management in the acute postoperative period.
Intervention and Implementation Plan: The revised pain medication administration guidelines
were implemented March 1, 2017. The following data points were compared to evaluate impact:
PACU LOS, patient satisfaction scores, PACU discharge pain scores, and costs for antiemetics
and oral (PO) and IV pain medications. Pre-implementation data includes a three-month sample
from 2016. Post-implementation data includes three-month samples in 2017, 2018, 2019, and
2020. PACU nurses were surveyed in January 2021.
Project Outcomes: Patients who received only PO and/or IV pain medications in PACU had:
average LOS decrease 8%, IV narcotic costs decrease 5%, analgesic costs decrease 2%,
discharge pain scores increase 12%, and antiemetic costs increase 68%. Nurses’ perceptions of
the guidelines on their practice and patient outcomes were positive, and patient satisfaction
scores were stable.
Keywords: PACU, guidelines, medication costs, pain scores, length-of-stay, satisfaction
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Using Revised Pain Medication Administration Guidelines in Post Anesthesia Care Unit
(PACU): A Program Evaluation
Purpose of the Evaluation
The purpose of this program evaluation is to determine if implementation of revised pain
medication administration guidelines in PACU led to improved patient satisfaction scores, lower
pain scores at discharge from PACU, lower medication costs, fewer rescue antiemetics being
administered, and shorter PACU lengths-of-stay at the clinical site.
Origins and Goals of Effort
A level-one trauma center’s surgical services department post-anesthesia care unit
(PACU) revised the pain medication administration clinical guidelines in response to Det Norske
Veritas Healthcare, Inc. (DNV) findings during a hospital accreditation survey. DNV is an
approved Centers for Medicare and Medicaid Services (CMS) accreditor. The hospital was cited
for improper ordering of medications leading to medication administration non-conformity in
January of 2017. Pain medication orders lacked appropriate pain medication administration
guidelines, which resulted in nurses choosing which pain medications to give and at what doses.
This was a problem throughout the hospital, so revision of pain medication order sets became
part of a hospital-wide initiative. The revision of pain medication administration guidelines for
PACU was also necessary because the average PACU length-of-stay (LOS) was consistently
longer than the national benchmark of two hours, and this was largely due to pain management
issues and overreliance on IV narcotics to treat pain. Extended LOS in PACU negatively affected
the operating room (OR) schedule. Monitoring patients in the OR once surgery was completed
due to inability to transfer to PACU caused delays for the cases to follow, which resulted in
frustrated patients, surgeons, and staff, and increased costs. The PACU nurse manager led the
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change to revise the pain medication administration clinical guidelines for immediate
postoperative adult patients in PACU, and the chief physician anesthesiologist authored the
guideline revisions. The guidelines were revised to clarify which medications were to be given
for “acute” pain or for “post-acute” pain while the patient was in PACU. The postoperative pain
medication order sets in PACU were altered to include the revised guidelines in March 2017, but
only LOS was evaluated, and a comprehensive evaluation was not performed to assess impact of
the change. This author conducted a formal program evaluation of the revised pain medication
administration clinical guidelines as a DNP project.
Target Population, Activities, and Services
The population for this program evaluation was immediate postoperative adult patients in
PACU at one clinical site, an urban level-one trauma center in a city in Hennepin County in the
Minneapolis-St. Paul metropolitan area in the state of Minnesota. The county is large, covering
approximately 610 square miles. Hennepin County is home to the city of Minneapolis, and fortyfour other cities (Your Government, Overview: Learn About the County, 2020). Minnesota’s
population in 2018 was 5,519,952, and the population of Hennepin County was 1,232,483 (The
University of Wisconsin Population Health Institute, 2019). Hennepin County is part of a sevencounty metropolitan area (Wright & Roesler, 2019). Detailed demographic information for
Hennepin County and the state of Minnesota, adapted from the County Health Rankings and
Roadmaps website, can be found in Appendix A.
The PACU at the clinical site recovered 10,302 patients in 2018 and 10,032 patients in
2019. Parties affected by the quality improvement project included postoperative adult patients
and the staff who provided direct patient care after surgery. The quality improvement project was
implemented March 1 of 2017, and patient involvement started on admission to PACU from the
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operating room after surgery and ended on discharge from the PACU. The reason for the quality
improvement project was to not only meet DNV accreditation requirements, but also to reduce
PACU LOS and provide effective treatment of postoperative pain through utilization of revised
pain medication administration guidelines by PACU nursing staff, with the expectation of
judicious administration of opioids and minimized reliance on IV opioids for postoperative pain
control in the patient population.
Review of Related Research
Opioid Crisis and the Postoperative Pain Connection
The opioid crisis in the United States has been a major focus of the Centers for Medicare
and Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC), and state and
county health departments in recent years. According to the CDC (2011), 73.8% of deaths
caused by prescription medication overdoses involved opioid pain relievers. Sale rates of opioids
from 1999 to 2010, and overdose death rates from 1999 to 2008, both quadrupled. The treatment
admission rate for substance abuse was almost six times higher in 2009 compared to 1999
(Centers for Disease Control & Prevention, 2011). According to the CDC website, there were
over 17,000 opioid overdose deaths resulting from prescription opioids in the United States in
2017. That is approximately 46 deaths per day, and the number is considered undercounted
because deaths due to synthetic opioids other than methadone, as well as overdose deaths where
the specific drug was not listed on the death certificate, are not included in the count. The reason
synthetic opioid prescription pain medications such as fentanyl and tramadol were not counted is
because the National Vital Statistics System (NVSS) does not distinguish between deaths caused
by pharmaceutical fentanyl vs illegally manufactured fentanyl (IMF) or other synthetic opioids
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that are pharmaceutical vs illegally manufactured (CDC's Response to the Opioid Overdose
Epidemic, 2019).
According to the CMS website and the Hospital Consumer Assessment of Healthcare
Providers and Systems (HCAHPS) Fact Sheet, pain management was a measured outcome on
HCAHPS surveys from October 2006 to December 2017, and HCAHPS scores were tied to
payment from CMS starting in 2012 as part of the “Hospital Value-Based Purchasing program”
(Centers for Medicare & Medicaid Services website, n.d.; "HCAHPS Fact Sheet," 2017). Pain
management as a measured outcome on HCAHPS surveys followed by CMS payment being
impacted by pain management satisfaction scores is thought to be one of the contributors to
overprescribing of opioid pain relievers and increase in abuse of these medications. In response
to the opioid epidemic, CMS replaced the pain management questions on the HCAHPS survey
with questions that focused on communication about pain. This change affected surveys for
patients discharged in January 2018 and beyond. Starting in October 2019, all pain
communication questions were eliminated from the HCAHPS survey. Removal of these
questions was intended to help CMS “comply with the requirements of the Substance UseDisorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and
Communities Act” ("HCAHPS changes," 2018).
The state of Minnesota is not immune to the opioid epidemic. The Minnesota Department
of Health reported that non-fatal opioid overdoses resulted in 2,037 emergency room visits in
2017, and 860 of those did not involve heroin. The number of people in 2014 admitted to the
hospital for opioid use disorder was 304.3 per 100,000, and 736.3 per 100,000 were admitted to
the hospital for treatment of chronic pain. The number of people admitted to treatment for opioid
abuse in 2015 was 10,332 (Opioid Overdose Prevention, 2019). According to a report written by
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Wright and Roesler (2019), drug overdose rates that involved opioids increased by 7% and
overall drug overdose rates increased by 9% in the state of Minnesota from 2016 to 2017. The
largest increase was seen in the seven-county Minneapolis-St. Paul metropolitan area, but there
was also an increase noted in greater Minnesota. In one year, from 2016 to 2017, the statewide
deaths that involved overdose of synthetic opioids such as fentanyl increased by 86%, while the
overdoses involving heroin decreased 26%. In the seven-county metropolitan area over the same
period, synthetic opioids were involved in 97% of opioid-involved deaths, and heroin overdose
deaths decreased by 17%. In the metropolitan area and greater Minnesota in 2017, the age group
with the greatest numbers of opioid overdose deaths were people 45-54 years old, and a higher
proportion of males than females died from drug overdoses (males 62%, females 38%). Though
the overall drug overdose mortality rate for Minnesota is among the lowest in the nation (44 out
of 50), there are significant racial disparities. The state was ranked number one when measuring
the disparity between African Americans and Caucasian people for overdose deaths. According
to the authors of the report, the racial disparities have gotten worse. From 2015 to 2017,
statewide drug overdose mortality rates for American Indians went from 47.3 to 76.2 per
100,000 residents, and rates for African Americans increased from 20.8 to 27.6 per 100,000. In
contrast, during the same 3 years, statewide drug overdose mortality rates for Caucasians
increased from 10.1 to 12.1 per 100,000. The report did not separate prescription vs. illegal
opioid overdose deaths (Wright & Roesler, 2019).
Groups who are at greater risk of developing opioid use disorder are men, middle-aged
adults, those living in rural areas, and Caucasians, American Indians, and Alaska Natives
(Centers for Disease Control and Prevention [CDC], 2011). Opioid abuse can start with legal
opioids prescribed for pain, and surgery can be a catalyst for the development of prescription
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opioid abuse. A retrospective cohort study by Alam, Gomes, Zheng, Mamdani, Juurlink, and
Bell (2012) concluded that older adult patients who were opioid naïve were 44% more likely to
use opioids long-term within 1 year of short-stay surgery if they were prescribed an opioid
within 7 days of surgery. The study included 391,139 opioid-naïve patients aged 66 or older who
had cataract surgery, a laparoscopic cholecystectomy, a transurethral resection of the prostate
(TURP), or varicose vein stripping surgery (Alam et al., 2012). According to a retrospective
analysis of 641,941 opioid naïve surgical patients by Sun, Darnall, Baker, and Mackey (2016),
chronic opioid use in the first year after surgery ranged from 0.119% up to 1.41%. Eleven
surgical procedures were included in the study: functional endoscopic sinus surgery (FESS),
cataract surgery, TURP, total knee arthroplasty (TKA), total hip arthroplasty (THA), open
cholecystectomy, laparoscopic cholecystectomy, open appendectomy, laparoscopic
appendectomy, cesarean delivery, and simple mastectomy. The surgery with the highest
incidence of chronic opioid use in the first year was total knee arthroplasty. Total hip
arthroplasty surgery was also listed as high risk for the development of chronic opioid use in the
first year after surgery. The authors identified that those who were most vulnerable to the
development of chronic opioid use were men, people older than age 50, and people with a
preoperative history of depression, antidepressant use, benzodiazepine use, alcohol abuse, or
drug abuse (Sun et al., 2016). All the surgical procedures included in the studies by Sun, Darnall,
Baker, & Mackey (2016) and Alam, Gomes, Zheng, Mamdani, Juurlink, and Bell (2012) are
performed at the clinical site where this program evaluation took place. Overreliance on opioids
in the postoperative period can result in patients experiencing opioid-induced side effects, which
require additional medications or interventions and can delay discharge from PACU in the short
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term and can have larger implications related to the opioid epidemic, including an increase in
abuse of prescription opioids.
Multimodal Analgesia for Pain Management
According to Gan (2017), inadequately managed acute postoperative pain affects a
significant segment of postoperative patients. Negative consequences of poorly managed acute
postoperative pain include diminished function and quality of life, compromised surgical
recovery, extended use of opioids, development of chronic postoperative pain, and increased
morbidity and medical costs (Gan, 2017). It is crucial to ensure that pain will be managed
effectively in the acute postoperative period. Opioids are commonly administered perioperatively
and postoperatively. It may not always be possible to eliminate the administration of opioids, but
there is an impetus to give as little narcotic as possible during and after the surgery, while still
providing adequate pain management. Non-opioid pain medications are effective in reducing the
need for opioid medications. Oral non-steroidal anti-inflammatory drugs (NSAIDS), both
selective and non-selective, and oral or intravenous acetaminophen/paracetamol significantly
reduced postoperative pain in several studies. The need for additional analgesia was significantly
reduced with acetaminophen/paracetamol (Liang et al., 2017; Maund et al., 2011), COX-2
inhibitors (Maund et al., 2011), and ibuprofen plus paracetamol (Derry et al., 2013). Given
together, acetaminophen and ibuprofen are more effective in the treatment of pain than when
given alone (Derry et al., 2013). Celecoxib 400mg provided longer pain relief than non-selective
NSAIDs and was as effective in relieving acute pain as ibuprofen 400mg (Derry & Moore,
2013). Serious adverse events associated with oral analgesics were rare (1 in 3200), and were
mainly seen with opioids, opioid combination drugs, and ibuprofen plus caffeine (Moore et al.,
2015). The need for rescue opioid pain medications was reduced when NSAIDs, acetaminophen,
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or COX-2 inhibitors were used as part of a multimodal pain approach (Liang, et al., 2017; Derry,
et al., 2013; Maund, et al., 2011). A literature synthesis table (Appendix B) includes details on
each study.
Multimodal analgesia is practiced by using more than one family of analgesic
medications to target different receptors in the body, rather than just one type of receptor, to
provide more comprehensive pain relief and minimize side effects. Multimodal analgesia also
typically involves more than one route of medication administration to treat pain. An example of
multimodal analgesia could include patient-controlled epidural analgesia with local anesthetic
and opioid, scheduled oral acetaminophen, and IV opioids as needed for breakthrough pain.
American Pain Society Guidelines (2016) were compared to UpToDate recommendations
(2020), and both guidelines recommended multimodal approaches in the management of acute
perioperative pain. These approaches included combinations of analgesic medications like
NSAIDs, acetaminophen, COX-2 inhibitors, gabapentinoids, NMDA receptor antagonists,
opioids, local anesthetics, as well as medications that are not meant to treat pain but have shown
synergistic effects or may potentiate other pain medications. Recommendations for medications
and routes of administration varied based on surgery type, length of time postoperative analgesia
would be needed, patient history of opioid dependence, and whether the patient was taking
buprenorphine or methadone preoperatively (Chou et al., 2016; Mariano et al., 2020).
Multimodal analgesia is an effective approach to manage pain in surgical patients and can reduce
the need for opioid analgesics.
Overview and Description of the Program Evaluation
The W.K. Kellogg Foundation’s (WKKF) Evaluation Guide (2017) steps are applied to
this program evaluation project. Stakeholders are involved in all stages of the program evaluation
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and are considered an important resource to the evaluator and the evaluation process. The
WKKF guide for program evaluation has seven stages: A. preparation, B. determination of
stakeholders and stakeholder engagement opportunities, C. identification of assumptions of what
the results will be, D. development of a plan for evaluation, E. collection and analysis of data, F.
communication of results and interpretation and facilitation of learning, G. use what was learned
to determine next steps (W.K. Kellogg Foundation [WKKF], 2017). The overview and
description of the program evaluation encompasses WKKF stages A-D. WKKF stage E is
represented in the evaluation design, stage F in the evaluation results, and stage G in the
summary, conclusion, and recommendations.
Preparation
The most appropriate evaluation type for the improvement project is an outcome
evaluation because the project was implemented in 2017 and no changes were made to the
guidelines since implementation. The evaluation approach is mainly systems-oriented, as the
project was implemented in a complex environment. Preoperative and intraoperative
management could affect pain management and antiemetic requirements in PACU, and PACU
nurses could choose to ignore the guidelines or make other care decisions unrelated to the project
that effect a patient’s ability to meet discharge criteria. The methods utilized are primarily
quantitative in nature, but some qualitative feedback was obtained from PACU nurses. Data
captured during patients’ stays in PACU was collected from before the implementation of the
guidelines and compared to data after the implementation. The qualitative and quantitative
survey data from PACU nurses was obtained in January of 2021 after the guidelines had been
implemented and utilized for approximately four calendar years. The DNP student was not an
employee of the institution and served as an external evaluator.
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Stakeholders
The following stakeholders were identified: patients, PACU nurse manager, anesthesia
department, PACU nurses, quality improvement (QI) department, pharmacy department, surgical
services administration, financial department, surgeons, and the evaluator (DNP student). The
PACU nurse manager and a nurse anesthetist served as clinical site preceptors for the evaluator
and were consulted through each stage of the evaluation project and for data collection. Staff
from the pharmacy department were consulted for data sources and data collection related to
medications. The QI Department director was consulted to clarify the DNV citation specific to
PACU and other details relevant to the QI project implementation. PACU nurses were consulted
on their perceptions of the implementation, use, and impact of the revised pain medication
administration guidelines on their practice and patient outcomes.
Assumptions
The initial theory of change for the project was that revised pain medication
administration guidelines would meet DNV accreditation requirements and lead to a reduction of
PACU length-of-stay. The expectation was that PACU nurses would have better guidance in
determining which pain medications and doses were appropriate to give to patients. Additionally,
pain would be managed, and side-effects would be minimized to allow patients to meet discharge
criteria sooner. During reconstruction of the logic model with stakeholders after the guidelines
had been implemented, it was determined that it may be beneficial to evaluate a broader set of
outcomes beyond length-of stay and meeting accreditation requirements for medication orders.
The logic model (Appendix C) includes the additional outcomes that were expected.
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Evaluation Plan
Three aims were developed for the program evaluation. The first aim was to evaluate the
impact of the revised pain medication administration guidelines in PACU to determine if
implementation led to improved patient satisfaction scores, lower pain scores at discharge from
PACU, lower medication costs, fewer rescue antiemetics being administered, and shorter PACU
length-of-stay (LOS). The objective to meet the first aim was to complete an outcome evaluation
of the revised pain medication administration guidelines in PACU to determine the impact on
patient satisfaction scores, discharge pain scores, medication costs, number of antiemetic doses
administered, and LOS. The second aim was to evaluate baseline data on patient satisfaction
scores, PACU discharge pain scores, medication costs, number of antiemetic doses administered,
and PACU LOS prior to implementation of the revised pain medication administration
guidelines. The objective to meet the second aim was to review patient satisfaction data that was
obtained prior to implementation; complete a chart audit to determine baseline data on discharge
pain scores, medication costs, number of antiemetic doses administered, and LOS prior to
implementation of the revised pain medication administration guidelines. The third aim was to
determine the perceptions of PACU nurses regarding the utility and impact of the revised pain
medication administration guidelines on their practice and patient outcomes. The objective to
meet the third aim was to solicit written feedback from PACU nurses regarding their perceptions
on the utility and impact of the guidelines on their practice and patient outcomes.
Evaluation questions were identified through discussion with stakeholders and review of
the logic model objectives. The impact of the implementation of the revised pain medication
administration guidelines in PACU on patients, PACU nurses, and the institution was evaluated
by seeking answers for the following questions:
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Did PACU length-of-stay decrease after implementation?

•

Did PACU discharge pain scores change, or were they stable?

•

Did the cost of antiemetic medications or number of rescue antiemetic medications
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administered in PACU decrease after implementation?
•

Was there a change in overall PACU pain medication costs?

•

Was there an increase in oral pain medication costs?

•

Was there an increase in IV non-narcotic medication costs?

•

Was there a decrease in IV narcotic medication costs?

•

Did patient satisfaction survey scores change?

•

What were the perceptions of PACU nurses regarding the utility and impact of the
guidelines on their practice and on patient outcomes?
Evaluation Design

Data Collection and Analysis
The DNV citation occurred in January of 2017. Baseline aggregate data and patient
satisfaction survey scores were acquired from a 3-month sample prior to the DNV site visit, from
October 1 to December 31 of 2016. The quality improvement project was implemented March 1
of 2017, and 90.4% of PACU nurses had completed education by April 1 of 2017. Postimplementation data included three-month samples of aggregate data and patient satisfaction
survey scores for the following date ranges: April 1 to June 30 of 2017, 2018, and 2019, as well
as January 1 to March 31 of 2020. The decision was made to use January 1 to March 31 data for
the year 2020 because COVID-19 restrictions, that started in mid to late March of 2020 and
changed throughout 2020, affected surgical caseloads.
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Quantitative data from patient medical records was obtained by the PACU nurse
manager, a nurse anesthetist, and pharmacy staff using pre-existing reports in the electronic
medical record system (EPIC). Report data was shared with this program evaluator as encrypted
Excel files. The raw data from these reports was filtered to remove duplicate entries, pediatric
patients (under age 18 at time of surgery), and patients who did not have a procedure in the OR
and a subsequent PACU stay during the specified date ranges. Then each patient was assigned a
case number. Duplicate medication administrations and medication administrations outside of
each individual patient’s PACU stay were removed. Each medication administration was labeled
with the proper assigned case number, then any remaining patient identifiers were removed. The
removed patient identifiers included name, date of birth, medical record number, hospital
account record, and PACU log number. Patients were then separated into three groups for
comparison: patients who received only oral analgesics in PACU (PO group), patients who
received only IV analgesics in PACU (IV group), and patients who received a combination of
oral and IV analgesics in PACU (PO+IV group). Patients who received a combination of
medications that included other routes of administration such as intra-muscular injections,
epidural, or rectal were not included in the program evaluation. The data points compared were
PACU LOS, PACU discharge pain scores, and PACU pain medication and rescue antiemetic
medication costs.
Patient satisfaction survey data was obtained by the PACU nurse manager as a Press
Ganey report, which was sent to the evaluator in PDF format. The evaluator and stakeholders
determined that the most relevant question from the patient satisfaction survey was: “Staff ensure
you were comfortable". Scores for that question were extracted from the PDF report for the date
ranges included in the program evaluation and entered in an Excel spreadsheet.
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A written survey and letter of introduction (Appendix D) was emailed to a PACU nurse
who volunteered to champion the PACU staff survey portion of the program evaluation. The
PACU nurse then distributed the survey to the PACU nursing staff and collected the completed
surveys in an envelope at the PACU nurses’ station. Participation was voluntary. The survey
consisted of one yes/no question, fourteen questions on a Likert scale of 1-5, and six open-ended
questions. Nurses who were working in PACU at the time of the initial implementation of the
revised pain medication guidelines in March of 2017 were asked to complete the entire survey.
Nurses who began working in PACU after March 1 of 2017 were asked to complete questions
12-21. The staff was given three weeks in January of 2021 to complete the survey and place it in
an envelope at the PACU nurses’ station. The program evaluator was then able to pick up the
sealed envelope containing the completed surveys at the hospital’s front desk.
Evaluation Results
PACU Length-of-Stay
Baseline PACU LOS was determined by calculating the average LOS in minutes over the
three-month period of October 1 to December 31, 2016 for each of the three groups. Postimplementation PACU LOS for each of the three groups was determined by calculating the
average LOS in minutes of the following date ranges: April 1 to June 30 of 2017, 2018, and
2019; and January 1 to March 31 of 2020. The IV group had a 10-minute decrease, the PO group
had a 23-minute increase, the PO+IV group had a 34-minute decrease, and the three groups
combined had an overall decrease of 9 minutes in PACU LOS post-implementation (see Figure 1
and Appendix F, Table F1).
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Figure 1.

Minutes

Average PACU LOS
160
150
140
130
120
110
100
90
80

PO Group 27% increase (23
minutes)
IV Group 9% decrease (10
minutes)
PO+IV Group 22% decrease
(34 minutes)

2016

2017-2020

Overall (3 groups
combined) 8% decrease (9
minutes)

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

PACU Discharge Pain Scores
Baseline PACU discharge pain scores were determined by calculating the average
discharge pain score over the three-month period of October 1 to December 31, 2016 for each of
the three groups. Post-implementation PACU discharge pain scores for each of the three groups
were determined by calculating the average discharge pain scores of the following date ranges:
April 1 to June 30 of 2017, 2018, and 2019; and January 1 to March 31 of 2020. The IV group
average discharge pain score increased from 3.3 to 3.8, the PO group increased from 2.7 to 2.9,
and the PO+IV group decreased from 4.4 to 4.2 on a 0-10 pain scale post-implementation (see
Figure 2 and Appendix F, Table F2).
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Figure 2.

4.4
4.2

PO Group (8% increase)

3.8
IV Group (15% increase)

3.3
2.7

2016

2.9

PO+IV Group (4%
decrease)

2017-2020

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

Antiemetic Medication Costs
To calculate antiemetic medication costs, first a single cost per dose was assigned to each
antiemetic medication given in PACU. This cost per medication dose was determined by
calculating the average cost charged to patients within the evaluation date ranges in 2016-2020
for each antiemetic medication dose given in PACU (Appendix E). Baseline PACU antiemetic
medication costs for the program evaluation were determined by calculating the sum of
antiemetic medication doses and associated costs over the three-month period of October 1 to
December 31, 2016 for each of the three groups. Post-implementation PACU antiemetic
medication costs for each of the three groups were determined by calculating the average sum of
antiemetic medication doses and associated costs for the following date ranges: April 1 to June
30 of 2017, 2018, and 2019; and January 1 to March 31 of 2020. The IV group average
antiemetic medication costs increased by $175.66, the PO group costs increased by $107.36, and
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the PO+IV group increased $108.22 post-implementation. The overall antiemetic costs for the
three groups combined increased 68% ($310.50) (Figure 3 and Appendix F, Table F3).
Figure 3.

Total Antiemetic Costs
$900.00
$800.00
$700.00
$600.00
$500.00
$400.00
$300.00
$200.00
$100.00
$0.00

PO Group ($107.36
increase)

IV Group 38% increase
($175.66)
PO+IV Group ($108.22
increase)
3 groups combined 68%
increase ($310.50)
2016

2017-2020

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

Analgesic Medication Costs
To calculate analgesic medication costs, first a single cost per dose was assigned to each
analgesic medication given in PACU. This cost per medication dose was determined by
calculating the average cost charged to patients within the evaluation date ranges in 2016-2020
for each analgesic medication dose given in PACU (Appendix E). Baseline PACU analgesic
medication costs for the program evaluation were determined by calculating the sum of analgesic
medication doses and associated costs over the three-month period of October 1 to December 31,
2016 for each of the three groups. Post-implementation PACU analgesic medication costs for
each of the three groups were determined by calculating the average sum of analgesic medication
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doses and associated costs for the following date ranges: April 1 to June 30 of 2017, 2018, and
2019; and January 1 to March 31 of 2020. The IV group average analgesic medication costs
decreased by $8,205.05 (12%), the PO group costs increased by $426.18 (243%), and the PO+IV
group increased by $6,052.55 (212%) post-implementation. The analgesic costs for the three
groups combined decreased by $1,169.55 (2%) (see Figure 4 and Appendix F, Table F4).
Figure 4.

Total Analgesic Costs by Group
PO Group 243% increase
($426.18)

$70,000.00
$60,000.00

IV Group 12% decrease
($8,205.05)

$50,000.00
$40,000.00

PO+IV Group 212% increase
($6052.55)

$30,000.00
$20,000.00

3 groups combined 2%
decrease ($1,169.55)

$10,000.00
$0.00
2016

2017-2020

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

Comparisons were also made by analgesic type and route of administration for the three
groups combined. IV narcotic medication costs, excluding patient-controlled analgesia (PCA)
doses, decreased by $2,450.67 (5%). Narcotic and non-narcotic total PO analgesic costs
increased $987.67 (238%). IV non-narcotic analgesic costs increased $219.26 (1%) (see Figure 5
and Appendix F, Table F5).
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Figure 5.

Total Costs by Analgesic Type/Route of
Administration

Groups combined- IV
narcotic medications
(excludes PCA doses) 5%
decrease ($2450.67)
Groups combined- PO
analgesics 238% increase
($987.67)

$60,000.00
$50,000.00

$40,000.00
$30,000.00
$20,000.00

Groups combined- IV
non-narcotic analgesics
1% increase ($219.26)

$10,000.00
$0.00
2016

2017-2020

Patient Satisfaction Survey Scores
Baseline patient satisfaction survey scores for the clinical site were determined by
calculating the average percentage of each response for the question “Staff ensure you were
comfortable” over the three-month period of October 1 to December 31, 2016. Postimplementation patient satisfaction survey scores for the clinical site were determined by
calculating the average percentage of each response for the question “Staff ensure you were
comfortable” for the following date ranges: April 1 to June 30 of 2017, 2018, and 2019; and
January 1 to March 31 of 2020. The average percentage of patients who answered “Yes,
definitely” to the question “Staff ensure you were comfortable” remained stable, with a 0.24%
increase from 95.5% to 95.8% post-implementation. (see figure 6).
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Figure 6.

Question: Staff ensure you were comfortable
100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%

No
95.8%

95.5%

Yes, somewhat
Yes, definitely (0.24%
improvement)

0.0% 4.5%
2016 (Average n= 37)

0.5% 3.7%
2017-2020 (Average n= 65)

PACU Nurse Survey
Written feedback was solicited from PACU nurses. Question 1 was a yes/no question
asking if the nurse worked in PACU at the clinical site prior to March 1, 2017. Questions 2-15
were answered using a 1-5 Likert scale. Questions 2-11 had fewer responses because the nurses
who did not work in PACU until after the change was implemented were not able to answer
those questions. Out of 28 total PACU nurses on staff, 16 nurses answered the survey; 7 worked
in PACU prior to implementation of the revised pain medication administration guidelines, and 9
started working in PACU after implementation. Most nurses found the guidelines to be practical
and easy to use, they utilized them when deciding which medication to administer, and felt more
confident in treating pain. Nurses who worked in PACU prior to the change in the guidelines all
agreed that they gave more non-opioid medications, and most felt they gave less IV fentanyl and
more IV hydromorphone. Most felt they were treating pain differently, patients seemed more
satisfied, and the guidelines improved patient care (see Figure 7).
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Figure 7.

Nurse Survey Likert Scale Results
Strongly disagree=5

Disagree=4

Neither=3

Agree=2

0

5

-5
2.Treated post-operative pain differently
3. Guidelines improved patient care
4. Patients seemed more satisfied
5. Gave less IV fentanyl
6. Improved patient comfort
7. Gave more IV dilaudid
8. Changed the way I treated postoperative pain
9. Gave fewer IV opioid medications
10. Gave more oral pain medications
11. Gave more non-opioid pain medications
12. Helped me feel more confident in treating pain
13. Guidelines are practical
14. Utilize guidelines to help decide which medication to…
15. Guidelines are easy to use

2
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15
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5
6
4
5

1
2
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1
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3
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4
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3
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2
1
1

3

1

10
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Out of the 16 completed nurse surveys, 11 nurses included open-ended feedback. Themes
that were identified in those open-ended responses included patient outcomes, PACU LOS,
PACU standing orders, effect on practice, and quality improvement opportunities. Nurses
perceived shorter LOS, improved surgical thruput, improved outcomes, and happier patients with
better and quicker pain control. They felt the PACU standing orders need more non-opioid
options. PACU nurses also noted that variations in anesthesia providers’ intra-operative and
post-operative management affects their ability to effectively treat pain with the current options
in the standing orders. For the effect on their practice, nurses liked being able to use nursing
judgement to treat pain and found the guidelines convenient and helpful in directing pain
management. They also identified some opportunities for future quality improvement including a
focus on pre-operative medications and the pre-operative patient environment, continuing with
Enhanced Recovery After Surgery (ERAS) protocols, and developing more consistency between
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anesthesia providers’ pain management techniques intra-operatively and post-operatively (see
Table 1).
Table 1.
PACU Nurse Survey Qualitative Feedback Summary
Themes
Patient outcomes

PACU LOS

PACU standing orders

Effect on practice

Quality improvement
opportunities

Summary of Answers
•
•
•
•
•
•
•
•

•
•
•
•
•
•

Shortened LOS with better/quicker pain control
Improved outcomes
Happier patients with pain managed
Improved perception of surgical thruput
Shorter LOS
Decreased PACU recovery time
Need more non-opioid options
Variation in anesthesia providers’ intra-operative and postoperative management affects ability to effectively treat
pain with current options
Use nursing judgement to treat pain
Convenient
Helps direct and manage pain
Pre-operative medications and pre-operative patient
management (calming environment)
Continue with enhanced recovery after surgery (ERAS)
protocols and non-opioids prior to surgery
More consistency between anesthesia provider pain
management techniques intra-operatively and postoperatively

Summary, Conclusion, and Recommendations
Aim #1 was met: Evaluate the impact of the revised pain medication administration
guidelines in PACU to determine if implementation led to improved patient satisfaction scores,
lower pain scores at discharge from PACU, lower medication costs, fewer rescue antiemetics
being administered, and shorter PACU length-of-stay (LOS). Aim #2 was met: Establish baseline
data on patient satisfaction scores, PACU discharge pain scores, medication costs, number of
antiemetic doses administered, and PACU LOS prior to implementation of the revised pain
medication administration guidelines. Overall PACU LOS decreased by 9 minutes (8%) and
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discharge pain scores increased 12%, from 3.3 to 3.7 on a 0-10 pain scale. Average IV opioid
costs decreased by $2,450.67 (5%), and average oral analgesic costs and IV non-narcotic
analgesic costs increased $1,206.94 (6%). Antiemetic doses and the associated costs increased by
68% ($310.50) for the three groups combined. Despite the changes in pain scores and
medications being given, patient satisfaction scores were stable, with a 0.24% increase.
The low number of antiemetic doses administered in PACU before and after
implementation likely influenced the outcome. In addition to the low overall numbers of
antiemetics given, the need for antiemetics may be impacted by multiple factors such as surgical
procedure performed, patient age and sex, and anesthetic technique used. The numbers of cases
in the PO group (2016 n=10 and 2017-2020 average n=43) and PO+IV group (2016 n=16 and
2017-2020 average n=58) were low. The changes in PACU LOS, PACU discharge pain scores,
medication costs, and antiemetic doses administered for the PO group and PO+IV group could
be due to the low number of cases in those groups.
Aim #3 was met: Determine the perceptions of PACU nurses regarding the utility and
impact of the revised pain medication administration guidelines on their practice and on patient
outcomes. Nurses perceived that they gave more IV hydromorphone (Dilaudid), more non-opioid
medications, and less IV fentanyl. They also perceived having happier patients, improved
outcomes, and quicker, better pain control for patients as well as shorter PACU stays and
improved surgical thruput. PACU nurses felt the guidelines were practical, convenient, and easy
to use. They also felt more confident in treating pain and liked using nursing judgement to treat
pain.
Results of the program evaluation will be shared with clinical site stakeholders and could
be used as evidence to accreditors and hospital administration of ongoing evaluation. I
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recommend that the clinical site’s surgical services department consider implementing an
evidence-based multimodal pain management protocol, and that they consider more options for
non-narcotic analgesics in PACU. I also recommend they monitor the antiemetic needs and
explore possible causes if they continue to increase. The program evaluation could be expanded
to include Phase II recovery room and full years instead of 3-month samples for a more complete
picture. The evaluation could also be expanded to compare other variables such as service lines
or anesthetic given, or to include other analgesic medication routes of administration such as
intra-muscular injections, epidural medications, or rectal medications. Other hospital
departments could use this program evaluation as a template and modify it as needed.
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Appendix A: Demographics for Hennepin County and the State of Minnesota 2018 & 2019

Demographic information
Population
% below 18 years of age
% 65 and older
% Non-Hispanic African
American
% American Indian and
Alaskan Native
% Asian
% Native Hawaiian/Other
Pacific Islander
% Hispanic
% Non-Hispanic white
% not proficient in English
% Females
% Rural

Hennepin County
Hennepin
State of MN State of MN
2018
County 2019
2018
2019
1,232,483
1,252,024
5,519,952
5,576,606
22%
22%
23%
23.30%
13.20%
13.60%
15.10%
15.40%
12.70%

13.10%

6.00%

6.30%

1.10%
7.40%

1.10%
7.60%

1.30%
4.90%

1.40%
5.10%

0.10%
6.90%
69.60%
4%
50.60%
2.20%

0.10%
7%
68.90%
3%
50.50%
2.20%

0.10%
5%
80.60%
2%
50.20%
26.70%

0.10%
5.40%
79.90%
2%
50.20%
26.70%

Note. From County Health Rankings and Roadmaps, by The University of Wisconsin Population Health Institute, 2019
(http://www.countyhealthrankings.org/explore-health-rankings). Copyright 2019 by County Health Rankings. Reprinted with
permission.
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Appendix B: Literature Synthesis
Author
Evidence
and Date Type

Sample,
Sample
Size, Setting

Observable
Measures

Findings

Limitations

Evidence
Level,
Quality

Maund,
2011

Adult patients
requiring pain
relief
immediately after
major surgery; 60
trials ranging
from n=20 to 514

24-hour morphine
consumption when
paracetamol, NSAID, or
COX-2 inhibitors are given
in addition to morphine PCA

Decrease in 24 h morphine consumption when
paracetamol, NSAID, or COX-2 inhibitors are given in
addition to PCA morphine after surgery, with no clear
difference between them.

Did not account for any synergistic effects
between the non-opioid analgesics and
morphine.

1A

Quantitative;
Systematic
review with
meta-analysis

When paracetamol, NSAIDs, or COX-2 inhibitors were
added to patient-controlled analgesia (PCA) morphine,
there was a statistically signiﬁcant reduction in
morphine consumption.
Multimodal perioperative protocol and postoperative
protocol for painful surgeries where regional anesthesia
is not utilized.

Mariano,
2018

Non-research;
Clinical practice
guidelines

N/A

N/A

Liang, 2017

Research,
Systematic
review with
meta-analysis

Opioid consumption, postoperative pain scores,
gastrointestinal events
(nausea, vomiting).

Intravenous acetaminophen was efficacious for
reducing postoperative pain and opioid consumption
than the placebo following total joint arthroplasty.

Derry, 2013

Research;
Systematic
review with
meta-analysis

Four studies
included 534
adult patients in
the
acetaminophen
groups and 331
adult patients in
the control
groups.
Ten studies
(n=1785
participants);
Adults (>15
years) prescribed
any dose of
celecoxib or
placebo for
acute
postoperative
pain.

Primary outcome: number of
participants achieving at least
50% pain relief for the
treatment groups (200mg
celecoxib, 400mg celecoxib,
and placebo).
Secondary outcomes: Use of
rescue medications within 24
hours of surgery, median
time to rescue medications,
adverse events, withdrawals
from study

Celecoxib at its recommended dosage of 400 mg for
acute pain is an effective analgesic, equivalent to
ibuprofen 400 mg, but providing a longer duration of
pain relief than many traditional NSAIDs.

Did not take into consideration any effect
differences between the 3 non-opioids at
different levels of morphine consumption.

Some of the recommendations made were
based on lower quality studies and were
presented as something to consider in
patient care rather than a practice standard
to follow.
A limited number of studies were
available, and they were of moderate to
low quality. More RCTs are needed.

4A

The studies mainly involved dental surgery
patients, or dental and orthopedic surgery
patients.

1A

1B
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Author
Evidence
and Date Type

Sample,
Sample
Size, Setting

Observable
Measures

Findings

Limitations

Evidence
Level,
Quality

Derry, 2013

Three studies
(n=1647
participants);
adult
participants (>
15 years) with
established
postoperative
pain of moderate
to severe
intensity
following day
surgery or inpatient surgery.

Primary outcome:
Participants achieving at least
50% of maximum pain relief
over four to six hours for the
treatment groups (placebo,
ibuprofen, or ibuprofen +
paracetamol).
Secondary outcomes: Median
(or mean) time to use of
rescue medication; Number
of participants using rescue
medication; Number of
participants with: any
adverse event; any serious
adverse event (as reported in
the study); withdrawal due to
an adverse event; Other
withdrawals: withdrawals for
reasons other than lack of
efﬁcacy (participants using
rescue medication.)
Primary outcome: Number of
participants achieving at least
50% pain relief over 4 to 6
hours. Secondary outcomes:
Numbers of participants
using rescue medication over
speciﬁed time periods, time
to use of rescue medication,
adverse events, and
withdrawal from studies.

Fewer participants required rescue medication with the
ibuprofen + paracetamol combination than with placebo
or ibuprofen alone.

The studies used involved dental surgery
patients. There were only 3 studies
included in the review.

1A

The study is older (2009). Only one
treatment arm utilized doses of 800mg
ibuprofen. Most of the studies were on
dental surgery patients.

1A

Derry, 2009

Research;
Systematic
review with
meta-analysis

Research;
Systematic
review with
meta-analysis

Seventy-two
studies
compared
ibuprofen and
placebo (9186
participants)

Ibuprofen plus paracetamol combinations provided
better analgesia than either drug alone (at the same
dose), with a smaller chance of needing additional
analgesia over about eight hours, and with a smaller
chance of experiencing an adverse event.

A single dose of ibuprofen 400mg is an effective
analgesic, providing at least 50% pain relief to over half
of the treated patients with acute, moderate to severe,
postoperative pain.
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Author
Evidence
and Date Type

Sample,
Sample
Size, Setting

Observable
Measures

Findings

Limitations

Evidence
Level,
Quality

McNicol,
2016

Seventy-five
studies (7200
participants);
children or
adults with
postoperative
pain following
any kind of
surgery,
including dental,
who were able to
self-report pain
intensity or pain
relief.

Primary outcomes
1. Pain relief: number of
participants experiencing at
least 50% of maximum pain
relief over four or six hours
postintervention. 2. Pain
intensity: mean pain intensity
over both the four- and sixhour postintervention periods
in each treatment arm and
their corresponding standard
deviations (SD), and in turn
calculated the mean pain
difference between groups.
Secondary outcomes
Time to achieve 50% pain
relief, number of participants
requiring rescue medication
during the four to six hours
after administration of the
study drugs, mean time to
requiring rescue medication,
opioid consumption, patient
satisfaction, adverse events,
withdrawals.
The overall objective was to
provide an overview of
adverse event rates
associated with single dose
oral analgesics, compared
with placebo, for acute
postoperative pain in adults.

IV paracetamol and IV propacetamol are statistically
superior to placebo for the outcome of the proportion of
participants achieving at least 50% pain relief over four
or six hours.

Only one of the 75 studies had at least 200
participants in each study arm. Some nonblinded studies were used.

1B

Most participants were younger adults who
had dental surgery (molar extraction).

5A

Moore,
2015

Research;
Systematic
review with
meta-analysis

Non-research;
Literature review

Thirty-nine
Cochrane
Reviews
(approximately
350 studies and
35,000
participants);
Adults with
acute
postoperative
pain taking oral
analgesics.

Adverse events, serious
adverse events (including
death), and specific adverse
events for the drugs being
compared (NSAIDs, NSAIDs
given in combination with
non-opioid drugs,
paracetamol, opioids or
opioid combination drugs).

Neither IV paracetamol nor IV propacetamol were
clinically superior for any efﬁcacy outcome versus
other analgesic agents, such as nonsteroidal antiinﬂammatory drugs (NSAIDs) or opioids. Both offer an
advantage over oral paracetamol due to their faster
onset of action and in that many patients are unable to
tolerate oral medication post-surgically.

Serious adverse events were rare, occurring a rate of
about 1 in 3200 participants.
For several opioids and opioid combinations, the event
rate with active drug was signiﬁcantly higher than with
placebo. For most comparisons, there was no
statistically signiﬁcant difference between NSAID and
placebo. For
ibuprofen200mgplusparacetamol500mgandforibuprofen
400 mg plus paracetamol 1000 mg, the adverse event
rate with the combination was lower than with placebo.
For ibuprofen 200 mg plus caffeine 100 mg, the
adverse event rate with the combination was
statistically higher than with placebo. There was no
statistically signiﬁcant difference between paracetamol
and placebo for any comparison. There was no
difference between gabapentin and placebo.
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Author
Evidence
and Date Type

Sample,
Sample
Size, Setting

Observable
Measures

Findings

Limitations

Evidence
Level,
Quality

Moore,
2015

Thirty-nine
Cochrane
Reviews
(approximately
460 studies and
50,000
participants);
single dose oral
analgesics for
acute
postoperative
pain in adults
(aged 15 years
or greater).

The overall objective was to
summarize the efﬁcacy of
pharmaceutical interventions
for acute pain in adults with
at least moderate pain
following surgery who have
been given a single dose of
oral analgesic.

Long duration of action (eight hours or greater) was
found for etoricoxib 120 mg, diﬂunisal 500 mg,
paracetamol 650 mg plus oxycodone 10 mg, naproxen
500/550 mg, celecoxib 400 mg, and ibuprofen 400 mg
plus paracetamol 1000 mg.

Most of the studies involved dental surgery
patients.

5A

Non-research;
Literature review

Drugs for which Cochrane
reviews found no
information, drugs for which
Cochrane reviews found
inadequate information
(fewer than 200 participants
in comparisons in two
studies), drugs for which
Cochrane reviews found no
evidence of effect or
evidence of no effect, pairs
of drug and dose for which
Cochrane reviews found
evidence of effect, but where
results were potentially
subject to publication bias,
pairs of drug and dose for
which Cochrane reviews
found evidence of effect,
where results were reliable
and not subject to potential
publication bias, percentage
of participants achieving
target of at least 50%
maximum pain relief, time to
re-medication, percentage remedicating.

Fast acting formulations and ﬁxed dose combinations of
analgesics can produce good and often long-lasting
analgesia at relatively low doses.
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and Date Type

Sample,
Sample
Size, Setting

Chou, et al,
2016

N/A

Non-research;
Clinical practice
guidelines

Observable
Measures

35

Findings

Limitations

Evidence
Level,
Quality

Multimodal pain management protocol.

Some of the recommendations made were
based on lower quality studies and were
presented as something to consider in
patient care rather than a practice standard
to follow.

4A

Note: Adapted from “Lessons from Practice: Using the JHNEBP Tools” by D. Dang & S.L. Dearholt, Johns Hopkins Nursing Evidence-Based Practice: Model
and Guidelines (3rd ed., p.253), 2018, Sigma Theta Tau International. Copyright 2018 by Sigma Theta Tau International.
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Appendix C: Revised Pain Medication Administration Guidelines Logic Model
Inputs

Activities

•

•

•

•

Meeting time
with quality
improvement
(QI) department
and information
technology (IT)
department
Interdisciplinary
teamindependent
review of
materials and
meeting time for
planning
Medication
administrationmedications,
pharmacy costs,
lab work, staff, IV
tubing and other
equipment

•

•

•
•

Outputs

Assemble an
•
interdisciplinary
team to
determine details
of action plan
Secure IT staff to
build data
collection reports •
and make
changes to the
electronic
medical record
(change order
sets, set up
alerts)
Secure QI staff to
assist with
planning for the
project, data
collection, and
analysis
Communicate
the change to
staff
Implement
revised pain
medication
administration
guidelines in
PACU

PACU patients
whose pain was
treated utilizing
the revised pain
medication
administration
guidelines
Nurses who
utilized the
revised pain
medication
administration
guidelines to
treat
postoperative
pain

Outcomes
•
•

Short-term

Intermediate

Meet DNV
accreditation
requirement
Reduced
variability in
treatment of
postoperative
pain due to
revised pain
medication
administration
guidelines

•

•
•

•

Long-term

Stable or
•
improved
average pain
scores
•
PACU LOS
average will be
less than 2 hours
Patient
satisfaction
scores on
HCAHPS survey
questions related
to pain will be
stable or improve
Fewer antiemetic
medications will
be given to treat
nausea and
vomiting

Administration of
IV narcotics will
decrease
Administration of
oral analgesics or
non-narcotic IV
pain medications
will increase
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Appendix D: Letter of Introduction and PACU Nurse Survey
Dear fellow nurses,
I am a doctoral nursing student completing my Doctor of Nursing Practice degree through Duquesne
University School of Nursing in Pittsburgh (online program). I am working with your PACU manager, Chris
Kraulik, on a project to complete my doctoral requirements.
The PACU order sets were changed in March of 2017 to include more clear guidance for pain
medication administration. I am evaluating patient satisfaction scores and data on length-of-stay, admission
and discharge pain scores, pain medications and antiemetic medications given in PACU and their costs, and
PACU holds before the change (April, May, June 2016 and October, November, December 2016) and after the
change (April, May, June of 2017, 2018, & 2019; January, February, March of 2020).
In addition to evaluating data from around 15,000 cases, I need your input regarding your perceptions
of the utility and impact of the guidelines on your practice and on patient outcomes. I created a survey with
some Likert scale questions for you to answer, as well as a few open-ended questions. Your survey answers
and input, along with the data from EPIC, will allow for a comprehensive evaluation of the change and may
lead to the discovery of other quality improvement opportunities in PACU. Your participation and opinions are
important for the success of the project, so please complete the survey. Your co-worker, Luanna Flaaen, has
graciously offered to help me distribute the survey to you all. I live in Minneapolis, but because of the
pandemic, I am not allowed to come to North Memorial myself. With your help, I will be able to complete my
degree by the end of spring semester 2021. Thank you in advance for completing the survey and being candid
in your responses.
Sincerely,
Elizabeth (Liz) Gerber
DNP student, CRNA, RN
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March 1, 2017 the pain medication order sets were updated for PACU. A significant focus of that
update included revising the guidelines for IV pain medication administration to the following:
Fentanyl 25-50mcg IV every 5 minutes as needed for acute surgical pain up to 200mcg while in recovery
area
Dilaudid 1mg/1mL syringe 0.2-0.4mg IV every 5 minutes as needed for 5 doses for post-acute pain
management while in recovery area.
In this survey, the terms “guidelines”, “revised pain medication guidelines”, “revised guidelines”, and
“pain medication guidelines” refer to the pain medication order sets used from March 1, 2017 to
present.
1. I worked as a PACU nurse at North
Circle one answer:
Memorial before March 1, 2017.
Yes
No (If no, skip to question #12)
2. I treated post-operative
pain differently after the
revised pain medication
guidelines were implemented.
3. Using the guidelines
improved patient care.
4. Patients seemed more
satisfied when I treated their
pain using the guidelines.
5. I gave less IV fentanyl to
patients after the guidelines
were implemented.
6. Using the guidelines
improved patient comfort.
7. I gave more IV dilaudid to
patients after the guidelines
were implemented.
8. I changed the way I treated
postoperative pain because of
the revised pain medication
guidelines.
38
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9. I gave fewer IV opioid
medications to patients after
the guidelines were
implemented.
10. I gave more oral pain
medications in PACU after the
guidelines were implemented.
11. I gave more non-opioid
pain medications in PACU
after the guidelines were
implemented.
12. Using the guidelines
helped me feel more
confident in treating pain.
13. The pain medication
guidelines are practical.
14. I utilize the pain
medication guidelines to help
me decide which medication
to administer.
15. The pain medication
guidelines are easy to use.
16. How did the guidelines affect your practice?
17. How did the guidelines affect patient outcomes?
18. How did the guidelines affect PACU length-of-stay?
19. What was your perception of the project to change the pain medication guidelines?
20. Please write anything else you would like to share about your experiences related to the change
itself (project, process, roll-out, staff education, communication, etc.) and your experiences using
the pain medication guidelines in patient care.

21. Please share any current opportunities for quality improvement in PACU.
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Appendix E: Average Charge Per Medication Dose
Medication
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS)
ACETAMINOPHEN 325 MG TABLET
ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION
ACETAMINOPHEN 500 MG TABLET
ASPIRIN 325 MG TABLET
BUTALBITAL-ASPIRIN-CAFFEINE 50 MG-325 MG-40 MG CAPSULE
FENTANYL (PF) 100 MCG/2 ML (50 MCG/ML) INTRAVENOUS SYRINGE
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 1 MG / 1 ML ORAL SYRINGE
HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
HYDROMORPHONE 2 MG TABLET
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE
HYDROMORPHONE 4 MG TABLET
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
MEPERIDINE (PF) 25 MG/ML INJECTION
MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
METHADONE 10 MG TABLET
METHADONE 10 MG/ML ORAL CONCENTRATE
MORPHINE 1-4 MG IV SOLUTION
MORPHINE 2 MG/ML INJECTION WRAPPER
MORPHINE 2-4 MG IV SOLUTION
MORPHINE ER 30 MG TABLET,EXTENDED RELEASE
MORPHINE ER 60 MG TABLET,EXTENDED RELEASE
NALBUPHINE 20 MG/ML INJECTION SOLUTION
ONDANSETRON 4 MG DISINTEGRATING TABLET
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
OXYCODONE 5 MG TABLET
OXYCODONE 5 MG/5 ML ORAL SOLUTION
OXYCODONE ER 20 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE 12 HR
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION
SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH

Average Charge
$99.40
$105.08
$4.22
$0.24
$9.49
$0.25
$2.84
$86.04
$40.49
$21.05
$40.40
$40.35
$42.91
$25.11
$41.56
$41.25
$15.39
$39.16
$21.11
$43.29
$42.30
$44.02
$21.07
$2.11
$32.05
$44.13
$44.08
$20.30
$28.12
$49.53
$20.92
$40.58
$8.75
$17.96
$25.99
$20.45
$49.68
$52.40

40

USING REVISED PAIN MEDICATION ADMINISTRATION

41

Appendix F: Supplemental Details for Figures
Table F1.
Average PACU LOS in Minutes
Year(s)

PO Group 27%
increase (23
minutes)

2016
2017-2020

IV Group 9%
decrease (10
minutes)
83
105

PO+IV Group 22%
decrease (34
minutes)
115
105

Overall (3 groups
combined) 8%
decrease (9
minutes)
154
116
120
107

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

Table F2.
Average PACU Discharge Pain Scores

Year (s)
2016
2017-2020

PO Group (8%
increase)

IV Group (15%
increase)
2.7
2.9

PO+IV Group (4%
decrease)
3.3
4.4
3.8
4.2

Three groups
combined (12%
increase)
3.3
3.7

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58. Scores are on a 0-10 pain scale.

Table F3.
Total Antiemetic Medication Costs Per Group

2016
2017-2020

PO Group
IV Group 38%
PO+IV Group
($107.36
increase
($108.22
3 groups combined 68% increase
increase)
($175.66)
increase)
($310.50)
$0.00
$458.22
$0.00
$458.22
$107.36
$633.87
$108.22
$768.72

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58
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Table F4.
Total Analgesic Medication Costs Per Group
Year(s)

2016
2017-2020

PO Group 243% IV Group 12%
PO+IV Group
3 groups combined 2%
increase
decrease
212% increase
decrease ($1,169.55)
($426.18)
($8,205.05)
($6052.55)
$175.22
$66,563.67
$2,851.79
$69,635.14
$601.39

$58,358.62

$8,904.35

$68,465.59

Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;
PO+IV group 2016 n=16 and 2017-2020 average n=58

Table F5.
Costs by Analgesic Type and Route of Administration
Year(s)

2016
2017-2020

Groups
combined
all
analgesics
2%
decrease
($1,169.55)

Groups
Groups combined- PO
Groups combined- IV
combined- IV analgesics 238% increase
non-narcotic analgesics
narcotic
($987.67)
1% increase ($219.26)
medications
(excludes PCA
doses) 5%
decrease
($2450.67)
$69,635.14
$47,871.45
$415.64
$20,443.69
$68,465.59
$45,420.78
$1,403.31
$20,662.95
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Appendix G: PO+IV Group Total Analgesic and Antiemetic Costs
Date
Count
Medication
2016
1 ACETAMINOPHEN 500 MG TABLET
2016
1 ASPIRIN 325 MG TABLET
2016
1 HYDROMORPHONE 4 MG TABLET
2016
2 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2016
3 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
2016
3 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
2016
4 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
2016
5 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2016
7 OXYCODONE 5 MG TABLET
2016
13 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
2016
36 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
2017
3 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
2017
3 ACETAMINOPHEN 325 MG TABLET
2017
4 ACETAMINOPHEN 500 MG TABLET
2017
4 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2017
4 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
2017
5 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
2017
6 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2017
13 OXYCODONE 5 MG TABLET
2017
23 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
2017
73 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
2018
1 ACETAMINOPHEN 325 MG TABLET
2018
1 HYDROMORPHONE 2 MG TABLET
2018
1 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
2018
2 ACETAMINOPHEN 500 MG TABLET
2018
4 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
2018
4 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
2018
5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2018

6 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE

Average Charge Total cost per med
Total cost per year
$9.49
$9.49
$2,851.79
$0.25
$0.25
$21.11
$21.11
$21.05
$42.09
$99.40
$298.21
$43.29
$129.87
$44.02
$176.07
$20.45
$102.24
$8.75
$61.27
$40.49
$526.33
$41.25
$1,484.86
$99.40
$298.21
$5,004.15
$4.22
$12.65
$9.49
$37.95
$21.05
$84.19
$44.02
$176.07
$43.29
$216.45
$20.45
$122.69
$8.75
$113.79
$40.49
$931.19
$41.25
$3,010.97
$4.22
$4.22
$3,116.86
$15.39
$15.39
$40.58
$40.58
$9.49
$18.98
$99.40
$397.62
$43.29
$173.16
$21.05
$105.24
$39.16

$234.94
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Date
2018
2018
2018
2018
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020

Count
7
10
10
36
1
1
2
5
5
6
8
14
19
28
42
44
48
188
1
2
2
3
5
8
11
12
13
16
22
56
58
151

Medication
OXYCODONE 5 MG TABLET
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
HYDROMORPHONE 2 MG TABLET
METHADONE 10 MG TABLET
MORPHINE 2 MG/ML INJECTION WRAPPER
ACETAMINOPHEN 325 MG TABLET
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
ACETAMINOPHEN 500 MG TABLET
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
OXYCODONE 5 MG TABLET
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
HYDROMORPHONE 1 MG / 1 ML ORAL SYRINGE
MORPHINE 2 MG/ML INJECTION WRAPPER
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
MEPERIDINE (PF) 25 MG/ML INJECTION
HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
ACETAMINOPHEN 500 MG TABLET
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
ACETAMINOPHEN 325 MG TABLET
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER
OXYCODONE 5 MG TABLET
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION

44
Average Charge
$8.75
$40.35
$20.45
$40.49
$15.39
$21.07
$44.13
$4.22
$40.58
$9.49
$43.29
$21.05
$99.40
$20.45
$39.16
$42.91
$8.75
$40.49
$25.11
$44.13
$40.58
$42.30
$21.05
$43.29
$9.49
$20.45
$4.22
$99.40
$40.40
$8.75
$42.91
$40.49

Total cost per med
$61.27
$403.49
$204.48
$1,457.52
$15.39
$21.07
$88.25
$21.08
$202.91
$56.93
$346.33
$294.66
$1,888.68
$572.53
$1,644.55
$1,887.97
$420.14
$7,611.48
$25.11
$88.25
$81.16
$126.90
$105.24
$346.33
$104.36
$245.37
$54.81
$1,590.46
$888.77
$490.16
$2,488.69
$6,113.47

Total cost per year

$15,071.95

$12,749.09
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Appendix H: IV Group Total Analgesic and Antiemetic Costs
Date
Count
Medication
2016
1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH
2016
10 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
2016
13 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX)
2016
40 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
2016
72 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
2016
170 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
2016
221 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
2016
847 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
2017
1 MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX)
2017
1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH
2017
2 NALBUPHINE 20 MG/ML INJECTION SOLUTION
2017
3 MORPHINE 2-4 MG IV SOLUTION
2017
5 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX)
2017
15 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
2017
39 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
2017
78 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
2017
187 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
2017
305 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
2017
861 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
2018
1 ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS)
2018
1 FENTANYL (PF) 2,500 MCG/50 ML PCA IV (PREMIX)
2018
1 ONDANSETRON 4 MG DISINTEGRATING TABLET
2018
2 MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX)
2018
2 PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION
2018
6 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX)
2018
13 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
2018
15 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (MIXTURE)
2018
26 MEPERIDINE (PF) 25 MG/ML INJECTION
2018
38 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE
2018
187 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION

Average Charge Total cost per med
Total cost per year
$52.40
$52.40
$67,021.89
$40.58
$405.81
$69.57
$904.36
$44.02
$1,760.73
$43.29
$3,116.93
$99.40
$16,898.67
$40.49
$8,947.54
$41.25
$34,935.44
$71.00
$71.00
$72,854.47
$52.40
$52.40
$49.53
$99.07
$44.08
$132.23
$69.57
$347.83
$40.58
$608.72
$44.02
$1,716.71
$43.29
$3,376.67
$99.40
$18,588.54
$40.49
$12,348.41
$41.25
$35,512.89
$105.08
$105.08
$48,449.84
$173.26
$173.26
$20.92
$20.92
$71.00
$142.00
$49.68
$99.36
$69.57
$417.40
$40.58
$527.56
$142.35
$2,135.19
$42.30
$1,099.76
$39.16
$1,487.93
$99.40
$18,588.54
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Date
2018
2018
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2019
2020
2020
2020
2020
2020
2020
2020
2020
2020
2020

Count
231
354
1
1
1
1
2
4
23
26
28
60
142
177
205
732
2
3
4
5
22
30
33
124
253
475

Medication
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS)
MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX)
NALBUPHINE 20 MG/ML INJECTION SOLUTION
PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION
MORPHINE 2 MG/ML INJECTION WRAPPER
HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX)
MEPERIDINE (PF) 25 MG/ML INJECTION
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
MORPHINE 2 MG/ML INJECTION WRAPPER
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX)
HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER
MEPERIDINE (PF) 25 MG/ML INJECTION
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION

46
Average Charge
$40.35
$40.49
$105.08
$71.00
$49.53
$49.68
$44.13
$69.57
$42.30
$40.58
$40.40
$43.29
$39.16
$99.40
$42.91
$40.49
$44.13
$40.58
$69.57
$41.56
$42.30
$40.40
$43.29
$99.40
$42.91
$40.49

Total cost per med
$9,320.59
$14,332.25
$105.08
$71.00
$49.53
$49.68
$88.25
$278.27
$972.87
$1,055.11
$1,131.17
$2,597.44
$5,560.15
$17,594.50
$8,796.22
$29,636.18
$88.25
$121.74
$278.27
$207.78
$930.57
$1,211.96
$1,428.59
$12,326.09
$10,855.82
$19,231.13

Total cost per year

$67,985.45

$46,680.21

46

USING REVISED PAIN MEDICATION ADMINISTRATION

47

Appendix I: PO Group Total Analgesic and Antiemetic Costs
Date
Count
Medication
2016
1 ACETAMINOPHEN 325 MG TABLET
2016
1 ACETAMINOPHEN 500 MG TABLET
2016
1 HYDROMORPHONE 2 MG TABLET
2016
2 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2016
5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2017
4 ACETAMINOPHEN 325 MG TABLET
2017
4 ACETAMINOPHEN 500 MG TABLET
2017
4 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2017
7 OXYCODONE 5 MG TABLET
2017
8 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2018
1 ASPIRIN 325 MG TABLET
2018
3 ACETAMINOPHEN 325 MG TABLET
2018
6 ACETAMINOPHEN 500 MG TABLET
2018
7 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2018
8 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2018
18 OXYCODONE 5 MG TABLET
2019
1 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION
2019
1 BUTALBITAL-ASPIRIN-CAFFEINE 50 MG-325 MG-40 MG CAPSULE
2019
1 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
2019
1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH
2019
5 ACETAMINOPHEN 325 MG TABLET
2019
5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
2019
9 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
2019
13 ACETAMINOPHEN 500 MG TABLET
2019
22 OXYCODONE 5 MG TABLET
2020
1 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION
2020
1 ASPIRIN 325 MG TABLET
2020
1 HYDROMORPHONE 2 MG TABLET
2020
1 METHADONE 10 MG TABLET
2020
1 MORPHINE ER 60 MG TABLET,EXTENDED RELEASE

Average Charge Total cost per med
Total cost per year
$4.22
$4.22
$175.22
$9.49
$9.49
$15.39
$15.39
$20.45
$40.90
$21.05
$105.24
$4.22
$16.87
$363.85
$9.49
$37.95
$21.05
$84.19
$8.75
$61.27
$20.45
$163.58
$0.25
$0.25
$538.29
$4.22
$12.65
$9.49
$56.93
$21.05
$147.33
$20.45
$163.58
$8.75
$157.55
$0.24
$0.24
$722.31
$2.84
$2.84
$40.58
$40.58
$52.40
$52.40
$4.22
$21.08
$21.05
$105.24
$20.45
$184.03
$9.49
$123.34
$8.75
$192.56
$0.24
$0.24
$995.86
$0.25
$0.25
$15.39
$15.39
$21.07
$21.07
$28.12
$28.12

47

USING REVISED PAIN MEDICATION ADMINISTRATION
Date
2020
2020
2020
2020
2020
2020
2020

Count
1
3
6
11
11
16
18

Medication
OXYCODONE 5 MG/5 ML ORAL SOLUTION
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION
ACETAMINOPHEN 325 MG TABLET
HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET
ACETAMINOPHEN 500 MG TABLET
OXYCODONE 5 MG TABLET

48
Average Charge
$17.96
$40.58
$4.22
$21.05
$20.45
$9.49
$8.75

Total cost per med
$17.96
$121.74
$25.30
$231.52
$224.92
$151.80
$157.55

Total cost per year
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Appendix J: All Groups IV Narcotic Costs Per Year
All Groups IV Narcotics (excludes PCA doses)- Sum of Total cost per year per medication

2016

2017

2018

2019

2020

FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER
HYDROMORPHONE 1 MG/ML INJECTION SYRINGE
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE
MEPERIDINE (PF) 25 MG/ML INJECTION
MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE
MORPHINE 2 MG/ML INJECTION WRAPPER
MORPHINE 2-4 MG IV SOLUTION
NALBUPHINE 20 MG/ML INJECTION SOLUTION
Grand Total

$9,514.35 $14,372.74 $15,789.77 $37,247.66 $25,344.60
$1,131.17 $2,036.11
$9,724.08
$10,046.87 $12,548.50
$206.23
$36,420.30 $38,523.85
$1,722.86 $7,204.70
$1,144.47 $1,012.42 $1,100.46
$1,936.80 $1,892.78
$176.50
$176.50
$132.23
$99.07
$49.53
$47,871.45 $55,020.67 $28,381.19 $56,868.85 $41,412.40
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Appendix K: Permission to Reprint Table
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